TITLE

Global clinical trial laboratories decentralize

AUTHOR(S)
Rosenberg, Ronald
PUB. DATE
April 2014
SOURCE
CenterWatch Monthly;Apr2014, Vol. 21 Issue 4, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that central laboratories which have played an important role in drug development, are now looking for decentralization and regional labs are becoming more active in global clinical trials. With sponsors seeking real-time data access and faster results, labs are conducting nearly all the necessary testing including those on complex analytical platforms, requiring esoteric testing and biomarker capabilities.
ACCESSION #
95386093

 

Related Articles

  • TRY TO REMEMBER. Belden, Heidi // Drug Topics;1/22/2007, Vol. 151 Issue 2, p28 

    The article discusses treatment and better disease identification aim to understand Alzheimer's disease (AD). The author reflects that although there is no cure for AD, causes of AD is being identified and new treatments that aim to destroy the buildup of amyloid plaques in the brain are being...

  • Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease. Zetterberg, Henrik; Mattsson, Niklas; Blennow, Kaj; Olsson, Olsson // Alzheimer's Research & Therapy;2010, Vol. 2 Issue 6, p1 

    In a slowly progressive disorder like Alzheimer disease, evaluation of the clinical effect of novel drug candidates requires large numbers of patients and extended treatment periods. Current cell- and animal-based disease models of Alzheimer disease are poor at predicting a positive treatment...

  • Can ‘phase IV’ work for you? Borfitz, Deborah // Medical Economics;6/6/2003, Vol. 80 Issue 11, p58 

    Focuses on the controversies behind phase IV clinical trials in the U.S. Emphasis on creating a potentiated drug combinations; Collaboration between doctors and pharmaceutical companies to increase drug sales; Quality of drug studies conducted.

  • N.O.'s research facilities prove big draw for clinical drug trials. Kamerick, Megan // New Orleans CityBusiness (1994 to 2008);10/20/2003, Vol. 24 Issue 17, p35 

    Reports on the prevalence of clinical drug trials in New Orleans, Louisiana. Number of trials taking place at the Louisiana State University Health Sciences Center; Impact of the prevalence of clinical trials on the economy of the city; Credibility of academic health science in conducting the...

  • Forest Laboratories: lercanidipine delay risks generic threat.  // PharmaWatch: Monthly Review;December2004, Vol. 3 Issue 12, p11 

    Reports that Forest Laboratories Inc. has announced that its antihypertensive drug candidate lercanidipine has failed in its Phase II clinical trial. Factors contributing to the clinical trial failure; Clinical description for lercanidipine; Impact of the Phase II trial failure on the company.

  • Targeted Cancer Therapies Lagging. Hampton, Tracy // JAMA: Journal of the American Medical Association;10/25/2006, Vol. 296 Issue 16, p1951 

    The article states that the U.S. Food and Drug Administration has created a new program called the Critical Path Initiative to improve the preclinical and clinical testing of drugs and medical devices used in the molecular diagnosis and treatment of cancer. The initiative will use biomarkers to...

  • Industry, FDA Warm to "Adaptive" Trials. Kuehn, Bridget M. // JAMA: Journal of the American Medical Association;10/25/2006, Vol. 296 Issue 16, p1955 

    The article states that the U.S. Food and Drug Administration has created new guidelines to recognize the trend of pharmaceutical companies evolving their clinical trials while still in progress, based on data achieved through the medical research studies. It is hoped that these adaptive...

  • OUTCOMES FOR DISEASE MODIFYING TRIALS. Wilcock, G. // Journal of Nutrition, Health & Aging;Jul/Aug2007, Vol. 11 Issue 4, p318 

    The article discusses the importance of clinical outcomes for Alzheimer's disease (AD) modifying drug trials. It notes that a randomized, parallel, two arm placebo-controlled design is the preferred approach because of its trial duration that shows balance between the time required to manifest a...

  • The Role of Tumor Tissue Architecture in Treatment Penetration and Efficacy: an Integrative Study. Rejniak, Katarzyna A.; Estrella, Veronica; Chen, Tingan; Cohen, Allison S.; Lloyd, Mark C.; Morse, David L. // Frontiers in Oncology;Apr2013, preceding p1 

    Despite the great progress that has been made in understanding cancer biology and the potential molecular targets for its treatment, the majority of drugs fail in the clinical trials. This may be attributed (at least in part) to the complexity of interstitial drug transport in the patient's...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics